July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Efficacy and Safety of AAV2.Flt23k Intraceptor Compared to AAV2.sFlt01
Author Affiliations & Notes
  • Xiaohui Zhang
    University of Utah, moran eye center, Salt lake city, Utah, United States
  • Hironori Uehara
    University of Utah, moran eye center, Salt lake city, Utah, United States
  • Lara S Carroll
    University of Utah, moran eye center, Salt lake city, Utah, United States
  • Bonnie Archer
    University of Utah, moran eye center, Salt lake city, Utah, United States
  • Balamurali K Ambati
    University of Utah, moran eye center, Salt lake city, Utah, United States
  • Footnotes
    Commercial Relationships   Xiaohui Zhang, None; Hironori Uehara, None; Lara S Carroll, None; Bonnie Archer, None; Balamurali Ambati, None
  • Footnotes
    Support  NIH grant 2R01EY17182
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1449. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xiaohui Zhang, Hironori Uehara, Lara S Carroll, Bonnie Archer, Balamurali K Ambati; Efficacy and Safety of AAV2.Flt23k Intraceptor Compared to AAV2.sFlt01. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1449.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intracellular VEGF should disrupt harmful autocrine VEGF feedback loops while avoiding damage to the neurosensory retina associated with chronic global VEGF suppression. We compared the efficacy and safety of intracellular versus extracellular suppression of vascular endothelial growth factor (VEGF) on laser-induced murine model of choroidal neovascularization (CNV). Inhibition of VEGF using AAV2.Flt23k intraceptors was compared to inhibition with soluble VEGF decoy receptor, AAV2.sFlt01.

Methods : AAV2.Flt23k, AAV2.LacZ, AAV2.AcGFP, and AAV2.sFlt01 were subretinally injected in 1 µl (5x108 vg) into C57/Bl6 mice. To assess efficacy, CNV was induced by argon laser (Iridex) one month after subretinal injection. CNV volume was measured two weeks after laser injury by optical coherence tomography (OCT). To evaluate safety, endoplasmic reticulum (ER) stress, TUNEL assay, and electroretinography (ERG) were assessed 4 months after subretinal injection.

Results : The mean CNV volume was significantly smaller in the AAV2.Flt23k (0.26 ± 0.02 × 106 µm3) group than control mice treated with AAV2.LacZ (0.97 ± 0.07 × 106 µm3, p<0.0001), PBS (1.15 ± 0.12 × 106 µm3, p<0.001), or no treatment (1.07 ± 0.07 × 106 µm3, p<0.0001), but not statistically different from AAV2.sFlt01 (0.29 ± 0.03 × 106 µm3, p>0.05). Neither AAV2.Flt23k nor AAV2.sFlt01 induced apoptosis or ER stress. ERGs of both treatments were normal. N=10 in each group. Statistical analysis was performed using one-way ANOVA.

Conclusions : AAV2.Flt23k showed similar efficacy and safety to AAV2.sFlt01 at two week and four month endpoints, respectively.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×